These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 36275693)

  • 1. B7-H3-targeting Fc-optimized antibody for induction of NK cell reactivity against sarcoma.
    Hagelstein I; Engel M; Hinterleitner C; Manz T; Märklin M; Jung G; Salih HR; Zekri L
    Front Immunol; 2022; 13():1002898. PubMed ID: 36275693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody.
    Stefańczyk SA; Hagelstein I; Lutz MS; Müller S; Holzmayer SJ; Jarjour G; Zekri L; Heitmann JS; Salih HR; Märklin M
    Blood Cancer J; 2024 Apr; 14(1):67. PubMed ID: 38637557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Fc-modified monoclonal antibody as novel treatment option for pancreatic cancer.
    Lutz MS; Wang K; Jung G; Salih HR; Hagelstein I
    Front Immunol; 2024; 15():1343929. PubMed ID: 38322253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia.
    Koerner SP; André MC; Leibold JS; Kousis PC; Kübler A; Pal M; Haen SP; Bühring HJ; Grosse-Hovest L; Jung G; Salih HR
    Leukemia; 2017 Feb; 31(2):459-469. PubMed ID: 27435001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Fc-Optimized CD133 Antibody for Induction of Natural Killer Cell Reactivity against Colorectal Cancer.
    Schmied BJ; Riegg F; Zekri L; Grosse-Hovest L; Bühring HJ; Jung G; Salih HR
    Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31181683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity.
    Loo D; Alderson RF; Chen FZ; Huang L; Zhang W; Gorlatov S; Burke S; Ciccarone V; Li H; Yang Y; Son T; Chen Y; Easton AN; Li JC; Rillema JR; Licea M; Fieger C; Liang TW; Mather JP; Koenig S; Stewart SJ; Johnson S; Bonvini E; Moore PA
    Clin Cancer Res; 2012 Jul; 18(14):3834-45. PubMed ID: 22615450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
    Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
    J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia.
    Steinbacher J; Baltz-Ghahremanpour K; Schmiedel BJ; Steinle A; Jung G; Kübler A; André MC; Grosse-Hovest L; Salih HR
    Int J Cancer; 2015 Mar; 136(5):1073-84. PubMed ID: 25046567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The bispecific B7H3xCD3 antibody CC-3 induces T cell immunity against bone and soft tissue sarcomas.
    Holzmayer SJ; Liebel K; Hagelstein I; Salih HR; Märklin M
    Front Immunol; 2024; 15():1391954. PubMed ID: 38765008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of NK Cell Reactivity against B-Cell Acute Lymphoblastic Leukemia by an Fc-Optimized FLT3 Antibody.
    Schmied BJ; Lutz MS; Riegg F; Zekri L; Heitmann JS; Bühring HJ; Jung G; Salih HR
    Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31817795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity against B Cell Acute Lymphoblastic Leukemia.
    Riegg F; Lutz MS; Schmied BJ; Heitmann JS; Queudeville M; Lang P; Jung G; Salih HR; Märklin M
    Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33915811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
    Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
    Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines.
    Park JE; Kim SE; Keam B; Park HR; Kim S; Kim M; Kim TM; Doh J; Kim DW; Heo DS
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32830112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of DS-5573a: A novel afucosylated mAb directed at B7-H3 with potent antitumor activity.
    Nagase-Zembutsu A; Hirotani K; Yamato M; Yamaguchi J; Takata T; Yoshida M; Fukuchi K; Yazawa M; Takahashi S; Agatsuma T
    Cancer Sci; 2016 May; 107(5):674-81. PubMed ID: 26914241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
    Picarda E; Ohaegbulam KC; Zang X
    Clin Cancer Res; 2016 Jul; 22(14):3425-3431. PubMed ID: 27208063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCC.
    Wu H; Liu C; Yuan Q; Qiao Y; Ding Y; Duan L; Li W; Zhang M; Zhang X; Jiang Y; Lu J; Dong Z; Wang T; Liu K; Zhao J
    Oncoimmunology; 2023; 12(1):2282250. PubMed ID: 38126034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation and preclinical characterization of an NKp80-Fc fusion protein for redirected cytolysis of natural killer (NK) cells against leukemia.
    Deng G; Zheng X; Zhou J; Wei H; Tian Z; Sun R
    J Biol Chem; 2015 Sep; 290(37):22474-84. PubMed ID: 26198633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement.
    Pekar L; Klausz K; Busch M; Valldorf B; Kolmar H; Wesch D; Oberg HH; Krohn S; Boje AS; Gehlert CL; Toleikis L; Krah S; Gupta T; Rabinovich B; Zielonka S; Peipp M
    J Immunol; 2021 Jan; 206(1):225-236. PubMed ID: 33268483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-29c downregulates tumor-expressed B7-H3 to mediate the antitumor NK-cell functions in ovarian cancer.
    Deng M; Wu D; Zhang Y; Jin Z; Miao J
    Gynecol Oncol; 2021 Jul; 162(1):190-199. PubMed ID: 33875234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Identification and characterization of monoclonal antibody Y4F11 against human B7-H3].
    Shi Z; Hu Y; Chen H; Fu F; Zhang X
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Oct; 32(10):1402-1406. PubMed ID: 27667469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.